Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials | Synapse

⌘+K

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1OsteoporosisOriginal Research · 2019 · 2,571 citations
2Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenRCT · 2008 · 406 citations
3Romosozumab or Alendronate for Fracture Prevention in Women with OsteoporosisRCT · 2017 · 1,559 citations
4Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAXRCT · 2015 · 38 citations
5Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAXRisk Assessment · 2012 · 141 citations
6The Effect of Abaloparatide-SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE StudyRCT · 2017 · 52 citations
7Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture OutcomeRisk Assessment · 2018 · 80 citations
8Non‐randomized studies as a source of complementary, sequential or replacement evidence for randomized controlled trials in systematic reviews on the effects of interventionsRCT · 2013 · 248 citations
9Harnessing the personal health data explosionBMJ · 2026
10Lab leak disease outbreaks: the long, murky historyBMJ · 2026

More from University of Oxford